CNBC's Brian Sullivan & Amanda Drury share their gloomy and sunny stock picks, including Dendreon down 81% in the last year amid lawsuits over its cancer drug, Provenge.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT